PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Leader Biomedical launches comprehensive orthobiologics portfolio

FOR IMMEDIATE RELEASE: 23 February 2016 HONG KONG and AMSTERDAM: To better meet the need for biocompatible grafts with good osteoconductive properties, Leader Biomedical has launched the OssGro® range of synthetic grafts to complement its existing eTiss® line of human allografts used for spine, trauma, and orthopaedic indications. The company will also enter the sports medicine market with the X-grip® anterior cruciate ligament (ACL) reconstruction system. OssGro® relies on the proven combination of hydroxyapatite (HA) and Beta Tricalcium Phosphate (?TCP) to achieve a highly regulated resorption rate, mimicking real bone formation. Optimal micro- and macro porosity is achieved through a sophisticated process of synthesis, the use of a high-quality porogen, and controlled sublimation and sintering. The result is a line of highly osteoconductive grafts, ideal for cell colonisation and the free flow of interstitial fluids. The easy to handle OssGro® product range further simulates the formation of new bone through the release of calcium and phosphate ions and is easily able to absorb osteogenic proteins. Benefiting from the same cutting edge technology used in the production of OssGro® ; the X-grip® system includes a screw and optional affix sheath, which can be used to attach an autograft, or eTiss® allograft, tendon to the tibia and femur during ACL reconstruction surgeries. Leader Biomedical’s new orthobiologics portfolio now includes: OssGro® granules, OssGro® sticks, OssGro® wedges, OssGro® Strip, X-grip® screw, X-grip® sheath, and Ossfinity® . Ossfinity® is a resorbable hydrogel putty with hydroxyapatite (HA) and Beta Tricalcium Phosphate (?TCP), that acts as a carrier for rapid vascularisation and mineralisation. OssGro® Strip is composed of highly purified Type 1 porcine collagen for optimal handling and containment. To learn more about this new product range, we invite attendees to stop by the AAOS Annual Meeting – Booth #4077 (Hall WB) – March 2-4, 2016 and visit our corporate website (www.leaderbiomedical.com). F

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026